Close Menu

EGFR Biomarkers

News and reporting on EGFR biomarkers.

This article has been updated from an earlier version with additional information from Qiagen on its PMA filing for an EGFR mutation companion test.

Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.

Using a pharmacogenetic strategy to home in on a molecularly defined non-small cell lung cancer patient population, researchers have shown in a clinical trial that the investigational EGFR inhibitor afatinib significantly prolongs survival in patients with EGFR-mutated tumors.

Eli Lilly said last week that it received a complete response letter from the US Food and Drug Administration declining its application to market Erbitux as a first-line treatment for non-small cell lung cancer.

By Ben Butkus
Life Technologies this week announced the expansion of its TaqMan Mutation Detection Assays based on competitive allele-specific TaqMan, or Cast, PCR technology.

Qiagen Expands Companion Diagnostic Portfolio
Qiagen has received approval of its Therascreen EGFR Mutation Detection Kit RGQ from Japanese regulatory authorities.

This article was originally posted on Sept. 1.
Roche last week said that the European Commission has approved the use of Tarceva as a first-line monotherapy for non-small cell lung cancer in patients with EGFR activating mutations.

Continuing to expand the development program for its irreversible inhibitor of EGFR and HER2, afatinib, Boehringer Ingelheim Pharmaceuticals has launched two new Phase II studies — one investigating the drug as a treatment for inflammatory breast cancer and another for metastatic

Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.

Roche and Clovis Oncology to develop PCR-based companion IVD for EGFR mutations; Medco Health to offer MolecularMD's qRT-PCR test for BCR-ABL.

Pages

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.